English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

With the ever-increasing understanding of the complexity of human protein interactions that impact directly on the safety and efficacy of therapeutic interventions, so the responsibility of researchers and drug companies to fully characterize drug candidates becomes a more and more onerous task. Using conventional methods, like ELISA, to examine even the most obvious interaction of, for example, a therapeutic antibody can add weeks or months on to the development process and clog up R&amp;D programmes with thousands of man hours. And failure to fully examine the nature of important interactions may result in costly drug failures further down the pipeline.

A label-free alternative to ELISA: Protein interaction analysis in drug development and production